drugset / Trial / NCT04158700
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Timeline
- Start
- 2019-12-05
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3200882 | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |